Buck A. Rhodes Biomedical Consulting and Hypnotherapy, Inc

Curriculum Vitae Latest Update: October 2000

Buck A. Rhodes, Ph.D. President Buck A. Rhodes Biomedical Consulting and Hypnotherapy, Inc. 1005 Franciscan NE, Albuquerque, New Mexico, U.S.A. Radiopharmacologist, Hypnotist and Consultant Phone 505 765-1147, home 505 244-0777

EDUCATION:

New Mexico State University B.S. (honors) 1958 Agronomy New Mexico State University Graduate studies 1960 Chemistry U.S.P.H.S. Div. Radiol. Sciences In service training 1962 Radiation Safety The Johns Hopkins University Ph.D. 1966 Radiological Science The Alchemical Institute Master Hypnotist 1997 Hypnotherapy

RESEARCH AND PROFESSIONAL EXPERIENCE:

1960.62 Chemist, commissioned Corp. US PHS, Division of Radiological Science; Assigned to Cincinnati, OH and Farmington, NM 1962-66 Graduate Student and Graduate Assistant, The Johns Hopkins University 1966.75 Instructor, Assistant Professor, Associate Professor (Radiology and Radiological Science, The Johns Hopkins School of Medicine, Hygiene and Public Health 1975.76 Professor of Pharmacy and Radiology, Director of Radiopharmacy, University of Kansas Medical Center, Kansas City, KS 1976.81 Professor of Pharmacy and Radiology, Directory of Radiopharmacy, University of New Mexico, Albuquerque, NM 1981.85 Senior Vice President for Scientific Affairs, Summa Medical Corporation, Albuquerque, NM 1985.96 President and Founder, RhoMed Incorporated, Albuquerque, NM 1996- President and Founder, Buck A. Rhodes Biomedical Consulting and Hypnotherapy Inc. (dba Buck Inc.), Albuquerque, NM Federal Tax ID # 85 044 2075. 1005 Franscisan NE, Albuquerque, NM 87102 ph 505 765- 1147 1999- Consultant to Dean of the UNM College of Pharmacy

HONORS AND RESPONSIBILITIES

Board Member, Society of Nuclear Medicine Board Member and Chairman of the Examination Committee, American Board of Science in Nuclear Medicine Honorary Diplomat, American Board of Science in Nuclear Medicine Honorary Member, El Colegio Internacional De Medicos Nucleares A.C. BIOGRAPHICAL SUMMARY

Dr. Rhodes has served consultant to the International Atomic Energy Commission, and to a number of businesses such as 3M Company, Abbott Laboratories, etc. He has organized, chaired or co-chaired five international meetings. He has published about 200 scientific papers, 7 textbooks, and 8 audiovisual programs. He is inventor or co-inventor on 20 U.S. patents and numerous foreign patents. He has served as principal investigator for grants and contracts totaling over $5,000,000. He has prepared and submitted several Investigational New Drug (IND) applications with the U.S. Food and Drug Administration. Currently, a monoclonal antibody-based drug he invented for abscess imaging is awaiting approval before the U.S. FDA. Starting before completing his Ph.D. degree in 1966, Dr. Rhodes became a faculty member in Radiological Sciences and Radiology at The Johns Hopkins University. Here he was involved in the development and testing of new radioactive drugs, under the direction of Dr. Henry N. Wagner, Jr. He was also involved in quality control test development and development of new applications for radioactive drugs. Another aspect of his work was trouble shooting of adverse reactions. Dr. Rhodes was promoted to the level of Associate Professor by the time of his departured Hopkins. Dr. Rhodes was then appointed as Professor of Pharmacy and Radiology, and Director of Radiopharmacy, first at the University of Kansas and then at the University of New Mexico. He coauthored the first textbook in Radiopharmacy with Dr. Barbara Howard. As Director of The University of New Mexico Radiopharmacy, he was responsible for the formulation, distribution, marketing, customer relations, radiation safety, budgetary management and quality control of radiopharmaceuticals throughout the State of New Mexico including some sites in Texas and Mexico. Graduates of this program became leaders in the field and instituted commercial radiopharmacies nationally and internationally. He introduced the subject of clinical radiopharmacy at UNM, including the basic principles of clinical trial management. Another innovation was the use of video feedback in the training of pharmacists in giving cases reports before audiences. Dr. Rhodes joined industry in 1981, first as Senior Vice President for Scientific Affairs of Summa Medical Corporation and then as Co-Founder and President of RhoMed Inc. In 1996, Dr. Rhodes retired as President of RhoMed Inc. continuing to serve the company as a consultant for two additional years. During this time he organized Buck A. Rhodes BioMedical Consulting and Hypnotherapy Inc. Dr. Rhodes is a trained and certified Hypnotherapist. Dr. Rhodes has taught Radiopharmacy to technicians, physicians, scientists, and pharmacists. He co-authored the chapter on radiopharmaceuticals in Dr. Wagner’s first text book in Nuclear Medicine and introduced the word: radiopharmaceutical. Dr. Rhodes also chaired the Subcommittee on Adverse Reactions to Radiopharmaceuticals and edited the first textbook on quality control in nuclear medicine. Research interests have focused on formulations radiolabeled with I-123, Tc-99m, Re-186 and In-113m. In 1976, he began developing radiolabeled antibodies as diagnostic tracers and later worked with radiolabeled peptides. Many of the newly discovered radiopharmaceuticals become subject of patents in the U.S. and abroad. SAMPLE PUBLICATIONS: (this list is selected from some 200 publications)

1. Rhodes BA: Liquid scintillation counting of radioiodine. Anal. Chem. 37:995-997, 1965. 7. Wagner HN Jr, Rhodes BA: The Radiopharmaceutical. In: Prinicples of Nuclear Medicine, HN Wagner Jr. (ed.). Philadelphia, WB Saunders Co., 1968; pp 259-301 11. Rhodes BA, Zolle I, Buchanan, Wagner HN Jr: Radioacrtive microspheres for studies of the pulmonary circulation. Radiology 92: 1453-1460, 1969. 15. Strauss HW, Hurley PJ, Rhodes BA, Wagner HN Jr: Quantification of right- to-left transpulmonary shunts in man. J. Lab, Clin. Med. 74: 597-607, 1969. 17. Rhodes BA, Wagner HN Jr: Radiation physics. In: The Thryoid. SC Wermer (ed.) NY, Harper & Row, 1971. pp 163-184. 29. Rhodes BA: Low probability of allergic reaction to albumin microspheres. Letter-to-the-editor. J. Nucl. Med. 12:649-650, 1971. 35. Pavoni P, Moen T, Rhodes BA, Wagner HN Jr: Changes in Xe-133 clearances resulting from electrically induced muscle contractions. II. Study in man. J. Nucl. Biol. Med. 15:19-20, 1971. 36. Wagner HN Jr, Rhodes BA: Radioactive tracers in the diagnosis of cardiovascular disease. Progress in Cardiovasc. Dis. 15:1-24, 1972. 37. Rhodes BA, Greyson ND, Siegel ME, Giargiana FA Jr., White RI, Williams GM, Wagner HN Jr: The distribution of radioactive microspheres after intra- arterial injection in the legs of patients with peripheral vascular disease. Amer. J. Roentgenology, Radium Therapy & Nucl. Med. 118:814-819, 1973. 38. Rhodes BA, Kamanetz GS, Wagner HN Jr: The use of limulus testing to reduce the incidence of adverse reactions to cisternographic agents. Neurology 24:810-12, 1974. 62. Chen M, Rhodes BA, Larson SM, Wagner HN Jr: Sterility testing of radiopharmaceuticals. J. Nucl. Med. 15:1142-1144, 1974. 101. Ford L, Schroff A. Benson W. Atkins H. Rhodes BA: SNM drug problem reporting systm. J. Nucl. Med. 19:116-117, 1978. 108. Hladik WB III, Friedman BE, Adams RF, Rhodes: Instruction in radiopharmacy – a clinical approach. Amer. J. Pharm. Educ. 43: 27-31, 1979. 111. Rhodes BA: Teaching pharmacists to communicate well: Amer. Druggist, Nov. 1979, p 89. 114. Rhodes BA, Cordova MA: Adverse reactions to radiopharmaceuticals: Incidence in 1978 and associated symptoms. J. Nucl. Med. 21:1107-1110, 1980. 118. Rhodes BA. Torvestad DA, Breslow K, Burchiel SW, Austin RK: A kit for direct labeling of antibody and antibody fragments with Tc-99m. J. Nucl. Med 21:54, 1980. 125. Hladik WB III,Nigg KK, Rhodes BA: Drug induced changes in the biologic distribution of radiopharmaceuticals. Sem. Nucl. Med. 12:184-218, 1982. 143. Rhodes BA, Zamora PO, Newell KD, Valdez E: technetium-99m labeling of murine monoclonal antibody fragments. J. Nucl. Med., April 1986.